Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00206375 · ClinicalTrials.gov registry record · Phase 4

Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism

A Phase 4 study, sponsored by Baylor College of Medicine.

Terminated
Registry status
Phase 4
Development phase
16
Enrollment target

NCT00206375 is a Phase 4 study that was terminated before completion, run by Baylor College of Medicine. The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00206375, a Phase 4 study, was terminated before completion, sponsored by Baylor College of Medicine.

TERMINATED
Registry status
Phase 4
Development phase
16 participants
Enrollment target

Study Summary

The purpose of this study is to see if giving growth hormone and Lupron along with thyroid hormone will improve final height in patients with long term hypothyroidism. Lupron is a medicine which is used to delay puberty and to prevent early closure of growing bones which might increase growth potential. Growth hormone is used to restore growth rate. This study will include children with "short term" and "long term" hypothyroidism.

Interventions

  • DRUG Growth hormone
  • DRUG Growth hormone treatment and puberty

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2003-05
Est. Completion 2011-11
Phase Phase 4

Sponsor

Baylor College of Medicine

616 total trials

What the Registry Record Tells You About NCT00206375

The ClinicalTrials.gov registry entry for NCT00206375 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Growth hormone is the first listed.

NCT00206375 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00206375 about?

NCT00206375 is a clinical study titled "Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism". The purpose of this study is to see if giving growth hormone and Lupron along with thyroid hormone will improve final height in patients with long term hypothyroidism. Lupron is a medicine which is used to delay puberty and to prevent early closure of growing bones which might increase growth potent...

What is the current status of trial NCT00206375?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2003-05. Estimated completion is 2011-11.

What interventions are being tested in trial NCT00206375?

The interventions under investigation include: Growth hormone (DRUG), Growth hormone treatment and puberty (DRUG).

Who is sponsoring clinical trial NCT00206375?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.